Inventor · disambiguated record
Christoph Dahlhoff
Also filed as: DAHLHOFF CHRISTOPH
11 granted patents·6 pending applications·57 citations·filing 2016–2025
87Inventor score
Top patents by PatentIndex Score
17 records- 0197US10294300B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted May 21, 2019·37 cites·16 claims
- 0296US11591396B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2020·Granted Feb 28, 2023·5 cites·33 claims
- 0393US10683351B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2019·Granted Jun 16, 2020·4 cites·24 claims
- 0491US11692031B2Antibody constructs for CLDN18.2 and CD3AMGEN RES MUNICH GMBH·Filed 2019·Granted Jul 4, 2023·6 cites·18 claims
- 0586US11447567B2Antibody constructs for FLT3 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Sep 20, 2022·4 cites·18 claims
- 0684US12435139B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2022·Granted Oct 7, 2025·0 cites·12 claims
- 0783US2025340639A1Antibody constructs for dll3 and cd3AMGEN RES MUNICH GMBH·Filed 2025·Application pending·0 cites
- 0876US12304952B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2021·Granted May 20, 2025·0 cites·16 claims
- 0976US2025092133A1Bispecific antibody constructs for cdh3 and cd3AMGEN RES MUNICH GMBH·Filed 2024·Application pending·0 cites
- 1070US11028171B2Bispecific antibody constructs for CDH3 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Jun 8, 2021·1 cites·14 claims
- 1170US2024174745A1Antibody Constructs for CLDN18.2 and CD3AMGEN RES MUNICH GMBH·Filed 2023·Application pending·0 cites
- 1266US12258411B2Anti-CCR8 antibodies and uses thereofAMGEN INC·Filed 2022·Granted Mar 25, 2025·0 cites·29 claims
- 1366US11926666B2Bispecific antibody constructs for CDH3 and CD3AMGEN RES MUNICH GMBH·Filed 2021·Granted Mar 12, 2024·0 cites·22 claims
- 1466US2023272113A1Antibody constructs for flt3 and cd3AMGEN RES MUNICH GMBH·Filed 2022·Application pending·0 cites
- 1553US2025171549A1Anti-ccr8 antibodies and uses thereofAMGEN INC·Filed 2025·Application pending·0 cites
- 1653US2025129160A1T cell engager molecules and uses thereofAMGEN RES MUNICH GMBH·Filed 2022·Application pending·0 cites
- 1747US12258404B2Bispecific antibody construct directed to MUC17 and CD3AMGEN INC·Filed 2018·Granted Mar 25, 2025·0 cites·19 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →